Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:
“What happens to an ADC after its infusion in the circulation?
How does it interact with tumor and immune cells?
What mechanisms ultimately produce cancer response and resistance?
Take a deep dive in the molecular world of ADCs though our latest review article, led by Alfred ZIppelius and just published in Nature Reviews Cancer.”
Title: Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
Authors: Alfred Zippelius, Sara M. Tolaney, Paolo Tarantino, Joseph P. Balthasar, Greg M. Thurber
You Can Also Read:
Oncologist Near Me – Paolo Tarantino: Shaping the Future of Breast Cancer Treatment
